\n\t\t\t\t\t\tBy Sam Reisman (August 16, 2022, 4:07 PM EDT) — British drugmaker GW Pharmaceuticals said Monday in the Federal Circuit that a district judge was right to throw out claims brought by cannabis giant Canopy Growth, accusing the company allegedly created a process to make its flagship CBD drug Epidiolex.<\/p>\n
In a response brief filed Monday, the U.K.-based company said a federal judge in Texas was correct when it ruled in March that Canopy could not prevail on its infringement claims against GW.<\/p>\n
The appeal hinges on the lower court’s definition of a certain phrase related to the chemical extraction process involved in turning the cannabis plant into Epidiolex, a seizure\u2026<\/p>\n
In law, information is the key to success. You need to know what’s happening with clients, competitors, practice areas and industries. Law360 provides the intelligence you need to stay an expert and beat the competition.\n\t\t\t\t\t\t<\/p>\n
Access to case data within articles (numbers, files, courts, nature of claim, etc.) Access to attached documents, such as writings, petitions, complaints, decisions, motions, etc.<\/strong>
\n\t\t\t\t\t\t\tCreate custom alerts for specific article and case topics and more!<\/p>\n